Akamis Bio

Phase 1b FORTRESS Clinical Trial: Fully Enrolled

Akamis Bio is a clinical-stage oncology company with an early-stage investigational medicine in its pipeline for locally advanced rectal cancer.

Transgene Payload: Secreted CD40 agonist monoclonal antibody

Be part of a team dedicated to transforming care for colorectal cancer patients, where entrepreneurship is expected, exceptional performance is recognized and rewarded, and professional growth is a shared commitment.

Adrian Chan is a managing director at Sedgwick Yard, where he leads investments in early-stage life science companies focused on oncology and other disease areas. He previously served on the board of Acquity Group Ltd and led corporate administration and Asian business development.

The company says its team aims to use the T-SIGn platform to positively impact the lives of people living with cancer.

Dr. Bowden is CMO of Remix, which develops small molecule therapies to modulate RNA processing. He previously served as strategic advisor and CMO at Agios, overseeing clinical development that led to US approvals for IDHIFA and TIBSOVO.

The company is developing oncolytic immunotherapies for colorectal cancer that aim to attack tumors, potentially reduce the need for surgery, preserve colorectal function, and improve quality of life.

Akamis Bio is working to advance the standard of care in colorectal cancer by developing oncolytic immunotherapies which aim to provide new hope to people living with this devastating disease.

Akamis Bio reported that NG-350A combined with chemoradiotherapy achieved a 50% composite response rate among the first 10 patients in a Phase 1b trial for locally advanced rectal cancer.

Mar 2026 · MedPath TrialNews article

Akamis Bio announced $60 million in funding tied to the closing of a Series A Prime round and a strategic partnership to develop its lead clinical candidate, NG-350A. The clinical-stage oncology company uses its proprietary Tumor-Specific Immuno-Gene (T-SIGn) platform to deliver immunotherapeutic proteins, biomolecules, and transgene combinations for solid tumors.

Dec 2024 · Pulse 2.0News article

Akamis Bio's gene therapy will be given to pancreatic cancer patients in a cohort of the REVOLUTION platform trial. The cohort also receives Yervoy and chemotherapy; the trial is conducted by the Parker Institute for Cancer Immunotherapy and Cancer Research Institute.

Feb 2023 · genomeweb.comNews article

Akamis Bio, a transatlantic oncology company, enters 2023 with a new name, office space, and $30 million from blue-chip investors. The company develops tumor gene therapies.

Jan 2023 · Endpoints NewsNews article